Krystal Biotech Inc., a company developing gene therapies for rare skin disorders, has filed to raise up to $34.5 million in an IPO. Its two preclinical programs, KB-103 for dystrophic epidermolysis bullosa (DEB) and KB-104 for Netherton syndrome, employ an engineered viral vector based on herpes simplex virus 1 and skin-optimized gene transfer.